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Prophylaxis with neuraminidase inhibitors is important 
for  controlling  seasonal  influenza  outbreaks  in  long-term 
care settings. We used a stochastic individual-based model 
that simulates influenza virus transmission in a long-term 
care nursing home department to study the protection of-
fered to patients by different strategies of prophylaxis with 
oseltamivir  and  determined  the  effect  of  emerging  resis-
tance.  Without  resistance,  postexposure  and  continuous 
prophylaxis reduced the patient infection attack rate from 
0.19 to 0.13 (relative risk [RR] 0.67) and 0.05 (RR 0.23), 
respectively. Postexposure prophylaxis prevented more in-
fections per dose (118 and 323 daily doses needed to pre-
vent 1 infection, respectively) and required fewer doses per 
season than continuous prophylaxis. If resistance to osel-
tamivir was increased, both prophylaxis strategies became 
less efficacious and efficient, but postexposure prophylaxis 
posed a lower selection pressure for resistant virus strains. 
Extension of prophylaxis to healthcare workers offered little 
additional protection to patients.  
T
he prophylactic use of neuraminidase inhibitors is a key 
component of influenza outbreak control in healthcare 
institutions (1,2). Based on its proven efficacy in reduc-
ing susceptibility, duration of illness, and infectiousness in 
household studies (3–6), oseltamivir is now the antiviral 
agent recommended for prophylactic use in nursing homes. 
Although the efficacy of oseltamivir has not been exten-
sively assessed in the elderly, some observational and ex-
perimental studies suggest beneficial effects of both contin-
uous and postexposure prophylaxis in containing outbreaks 
and reducing the number of severe complications among 
nursing home residents (2,7–10).
During the 2007–08 and 2008–09 influenza seasons, the 
number of isolated influenza A (H1N1) viruses with resis-
tance to the neuraminidase inhibitor oseltamivir increased 
considerably  (11,12).  Following  the  emerging  resistance 
against the M2-inhibitors amantadine and rimantadine, the 
efficacy of this class of neuraminidase inhibitors may also 
be threatened (13). Given the speed at which resistant strains 
have spread and the large variability of influenza activity, it 
has been impossible to obtain evidence on how resistance 
has affected influenza control strategies from randomized 
controlled trials. This effect can, however, be derived using 
modeling studies (14,15). Therefore, we developed a math-
ematical model of influenza transmission in long-term care 
facilities to study different scenarios and to perform multi-
ple simulations that minimize the probability of chance out-
comes. We primarily determined the effect and efficiency 
of postexposure and continuous exposure prophylaxis strat-
egies with oseltamivir, as compared with no prophylaxis, 
on infection attack rates among patients in a long-term care 
nursing home department. We also determined the influence 
of increased introduction of resistant virus strains on both 
strategies and assessed the potential benefits of extending 
prophylaxis to healthcare workers (HCWs).
Methods
Population and Model
We simulated the occurrence of influenza virus out-
breaks during an 80-day period in a typical long-term care 
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nursing home department (30-bed unit with 15 two-bed 
rooms and a team of 30 HCWs) in the Netherlands. HCWs 
worked 8-hour shifts; according to a weekly schedule 5, 3, 
and 1 HCW(s) worked during the day, evening, and night 
shifts, respectively, which has been observed in some nurs-
ing homes in the Netherlands. The average length of stay 
for a patient was 14 months (16,17). Because we simulated 
a small population where chance events can have major ef-
fects, we used a stochastic transmission model. The model 
is described in the online supporting information (online 
Technical  Appendix,  available  from  www.cdc.gov/EID/
content/15/10/1547-Techapp.pdf) and has been described 
in detail in a previous study (18). Here, we describe the 
essential elements of the model’s structure for the baseline 
scenario (parameters for the baseline scenario are shown 
in Table 1).
Infection Cycle
According to a standard model for infectious disease 
transmission, persons could be in 1 of several stages of 
influenza virus infection: susceptible, infected but not yet 
infectious  (exposed),  infectious,  or  recovered/immune   
(Figure 1) (19). The durations of the exposed and infectious 
periods were exponentially distributed with means of 1.4 
days; the resulting generation time equaled 2.8 days, which 
agrees with observations of generation times during influ-
enza epidemics (20,21). At the start of the influenza season, 
30% of the adult nursing home population was assumed to 
be immune to infection because of cross protection from 
earlier infections (22). Since the elderly have weakened im-
mune systems (23,24), but exact estimates are absent, we 
made the most conservative assumption that their immune 
systems had no memory of previous infections.
Influenza Vaccination
According  to  our  model,  both  patients  and  HCWs 
could receive influenza vaccine before the influenza season. 
The average vaccination rate was 75% for nursing home 
patients (25) and 40% for HCWs (2). We assumed that 
for each person vaccination either led to perfect immunity 
against infection or had no effect (18). In a previous study, 
we showed that this all-or-nothing assumption for vaccine-
induced immunity yielded similar results to those of an 
alternative assumption of incomplete immunity in which 
vaccinated persons had a lower probability of acquiring in-
fection upon contact with an infectious person (18). The 
assumption of all-or-nothing immunity due to prophylaxis 
has also been made in other modeling studies (26). We as-
sumed the vaccine efficacy against influenza virus infec-
tion in healthy adults, and thus HCWs, was 73% (27). For 
elderly nursing home patients, no statistically significant 
vaccine efficacy against infection has been observed (28). 
However, because other evidence showed that the vaccine 
protected against influenza disease and complications, we 
assumed patient efficacy to be 25% (28,29).
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Table 1. Parameter values baseline scenario* 
Parameter Value Reference
  No. beds  30
  No. HCWs  30
  Time step (= shift), h  8 (18)
  Minimum duration of simulation, d  80
  Discharge/mortality rate, per d  1/425 (16,17)
  Rate of becoming infectious after infection, per d  1/1.4 (20,21)
  Infection recovery rate, d  1/1.4 (20,21)
  Prior immunity HCWs  30% (22)
  Prior immunity patients  0
  Vaccine uptake patients  75% (25)
  Vaccine uptake HCWs  40% (2)
  Vaccine efficacy (against infection) 
  Patients  25% (28)
  HCWs  73% (27)
  Transmission probability per casual contact  0.13 (18)
  Close/casual transmission probability ratio  2
  Mean visitor frequency/patient/d  0.7 (31)
  Minimum duration of postexposure prophylaxis, d  14 (2)
  Minimum duration of postexposure prophylaxis after last detected case, d  8 (2)
Parameters in uncertainty analyses 
  Probability of disease developing after infection (range)  0.5 (0.30–0.7)  (4)
  Probability of disease developing after infection, during prophylaxis (range)  0.2 (0.05–0.4)  (4)
  Oseltamivir efficacy against infection (range)  0.53 (0.2–0.8)  (4)
  Oseltamivir reduction in infectiousness (range)  0.2 (0–0.5)  (4)
*HCW, healthcare worker. Prophylaxis Strategies to Prevent Influenza
Prophylaxis with Oseltamivir
We compared 2 strategies of prophylaxis with oselta-
mivir to a control situation in which no neuraminidase in-
hibitors were used: continuous (seasonal) prophylaxis was 
given to all patients during 8 weeks (the longest period of 
prophylaxis described in effectiveness studies) (30) around 
the peak of the influenza season; or postexposure prophy-
laxis was started for all patients as soon as 1 patient had 
a laboratory-confirmed influenza virus infection. Because 
recognition  of  a  possible  influenza  infection  is  required 
before doing a laboratory test, we assumed that only the 
fraction of infected patients in whom influenza disease de-
veloped (the symptomatic patients) could trigger the start 
of postexposure prophylaxis. We assumed that, for every 
first symptomatically infected person, the delay between 
the start of infectiousness and the start of prophylaxis fol-
lowed a distribution with a mean of 3.5 days. This interval 
was determined by the time to onset of symptoms, the time 
to recognition of symptoms, the time to a positive labora-
tory test, and the delay to start of prophylaxis (online Tech-
nical Appendix). Postexposure prophylaxis was given to 
all patients in the department for at least 2 weeks and was 
continued until no new cases occurred during a period of 
8 days (2). Because we did not have data on the efficacy 
of oseltamivir in elderly persons, we used estimates from 
household studies (4) as the best available evidence. We 
assumed  oseltamivir  induced  immunity  to  infection  by 
wild-type strains in 55% of the susceptible patients as soon 
as it was administered and for the duration of prophylaxis. 
Immunity did not develop in the other patients, but when 
they were infected they were considered to become less 
infectious than persons who did not take oseltamivir (26). 
Based  on  estimates  of  the  total  reduction  in  infectious-
ness in persons treated with oseltamivir (4), we assumed 
the probability that the virus was transmitted during con-
tact with a susceptible person was reduced by 20%. In the 
online Technical Appendix, we describe some uncertainty 
analyses that we performed for the parameters describing 
oseltamivir efficacy.
Influenza Disease
On the basis of household studies, we assumed that in-
fluenza disease would develop in 50% of patients infected 
with influenza virus (4). For those receiving oseltamivir 
prophylaxis, this probability was only 20% (4).
Contacts
A  person’s  risk  of  being  infected  depended  on  the 
number and type of contacts with infectious persons. We 
distinguished  between  casual  and  close  contacts;  casual 
contact was considered as conversation and close contact 
occurred with physical contact. We parameterized the con-
tact model; the expected numbers of contacts, specified by 
type of persons and kind of contact, matched the number 
of contacts that we observed in 2 nursing home depart-
ments in the Netherlands (18). The probability of contact 
between 2 persons, given their type (HCW or patient), as 
well as the probability that this contact was close (physical 
contact), is given in Table 2. During the night shift, pa-
tients did not have contact with other patients, except for 
their roommates, who were assumed to be casual contacts. 
During the day and evening shifts, patients could also have 
contact with visitors. All contacts with visitors were con-
sidered close. The expected number of visitors was based 
on a study in the Netherlands on nursing home patients and 
visitors and was estimated to be 0.7 visitors per patient per 
day (31).
Transmission
For every pair of persons with a casual or close con-
tact, a probability existed that the virus was transmitted 
if the persons involved in the contact were infectious and 
susceptible. This probability was determined by sampling 
from a Bernoulli distribution with mean set equal to the 
transmission probability. For a casual contact, the trans-
mission probability was 0.13; we chose this probability be-
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Figure  1.  Schematic  diagram  of  our  stochastic  individual-based 
model. A)  The  different  types  of  persons  in  the  nursing  home: 
patients,  healthcare  workers  (HCWs),  and  visitors.  B) The  time 
course of infection: S, susceptible; E, exposed; Ia, infectious and 
asymptomatic;  Is,  infectious  and  symptomatic;  R,  recovered/
immune; Rp, immune while using prophylaxis. For all patients and 
HCWs in the model, we kept track of their stage in this infection 
cycle in time. If the influenza strain that is transmitted is resistant to 
oseltamivir, persons in the Rp department can still become infected 
(dashed arrow).RESEARCH
cause the expected infection attack rate among patients in 
the absence of HCW vaccination was similar to observed 
attack rates for influenza-like-illness (18,25,32). For close 
contacts, the probability of transmission was assumed to be 
2× as high as that of casual contacts.
Influenza in the Community
The rate at which influenza virus was introduced into 
the nursing home by HCWs, visitors, and patients depend-
ed on the prevalence of the virus in the community; we 
used a simulation of an influenza epidemic in a large popu-
lation (online Technical Appendix). In each simulation, a 
constant proportion of infections in the community was as-
sumed to be caused by resistant strains.
Oseltamivir Resistance
Resistant viruses were assumed to be completely in-
sensitive to oseltamivir, and therefore prophylaxis had no 
effect on the susceptibility of a person who was exposed 
to a resistant strain. We also assumed that use of oseltami-
vir neither affected the infectiousness nor the development 
of symptoms in a person infected with a resistant strain. 
Apart from oseltamivir sensitivity, resistant and nonresis-
tant strains were assumed to be similar. Infection with 1 of 
the strains conferred cross-protection against infection with 
other strains during the season.
Outcomes
We defined the infection attack rate and the disease at-
tack rate as the total number of infections or influenza dis-
eases among patients, respectively, divided by the total num-
ber of patients in the nursing home department during the 
study period. We distinguished between infections caused 
by oseltamivir-sensitive and -resistant strains and compared 
scenarios with increasing prevalence of oseltamivir resis-
tance. Based on the distribution of infection attack rates in 
a nursing home in the absence of preventive measures (18), 
we used the proportion of infection attack rates of >0.3 as a 
proxy for the probability of a large outbreak. We calculated 
the absolute and relative risk reductions for both strategies 
of prophylaxis (efficacy) and determined the fraction of in-
fections caused by resistant strains. We also computed the 
number of daily doses of prophylaxis needed to prevent 1 
infection or disease (DNP) as the total number of doses ad-
ministered divided by the number of influenza infections or 
diseases prevented (the absolute risk difference) (efficiency). 
Information on the statistical precision of the effect estimates 
can be found in the online Technical Appendix.
Alternative Scenarios
In  addition  to  the  baseline  scenario  previously  de-
scribed,  we  considered  an  alternative  scenario  in  which 
both patients and HCWs received continuous or postexpo-
sure prophylaxis according to the same rules. Postexposure 
prophylaxis was started after detection of infection in a pa-
tient and was given to all patients and all HCWs. We also 
studied a scenario in which the HCW vaccination rate was 
only 10%, as was observed in the Netherlands (33). Here 
we considered prophylaxis to patients only and to patients 
and HCWs.
In the online Technical Appendix, additional scenarios 
are described for the following circumstances: 1) differ-
ent delays between the start of infectiousness of the first 
symptomatic patient and the start of postexposure prophy-
laxis, 2) different levels of influenza virus activity in the 
community, 3) higher percentage of HCWs vaccinated, 4) 
lower patient vaccine uptake, 5) greater percentage of pa-
tients with prior immunity, and 6) a 60-bed nursing home 
department.
Results
Baseline Scenario
In the absence of resistance, the prophylactic use of 
oseltamivir reduced the number of influenza virus infec-
tions among patients during the influenza season. The in-
fection attack rate among patients decreased from 0.19 in 
the control setting without prophylaxis to 0.13 (relative risk 
[RR] 0.67) when postexposure prophylaxis was given to 
all patients (first 2 bars, Figure 2, panel A). The fraction 
of large outbreaks with an infection attack rate of >0.3 de-
creased from 0.31 to 0.17 (RR 0.55), and outbreaks with 
attack rates >0.4 rarely occurred (Figure 3). If continuous 
prophylaxis was given for 8 weeks, the infection attack rate 
decreased to 0.05 (RR 0.23) (Figure 2, panel B), and the 
percentage of large outbreaks decreased to 0.03 (RR 0.09). 
Because of continuous prophylaxis, not only did large out-
breaks disappear, but also the percentage of departments 
without any patient infection increased (Figure 3). Rates 
of influenza disease decreased from 0.10 to 0.06 (RR 0.60) 
and 0.01 (RR 0.13), respectively, for the 2 different strate-
gies of prophylaxis (Figure 1, panels C, D). Although the 
number of infections that could be prevented was higher for 
continuous prophylaxis, the DNP was ≈3× higher with this 
strategy than with postexposure strategy (Figure 4). With-
out resistance, the DNP was 118 for postexposure prophy-
laxis and 323 for continuous prophylaxis.
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Table 2. Contact probabilities between persons in a nursing 
home department* 
Person
Contacted
person
Probability of 
contact
Probability of close 
contact given casual 
contact
Patient Patient 0.07 0.06
Patient HCW 0.52 0.69
HCW HCW 0.91 0.31
*HCW, healthcare worker. Prophylaxis Strategies to Prevent Influenza
Resistance
An increase in the proportion of oseltamivir-resistant 
influenza virus strains in the community reduced the effi-
cacy of prophylaxis with oseltamivir against infection and 
disease (Figure 2). In addition, both prophylaxis strategies 
became less efficient and the DNP increased rapidly, in 
particular for the continuous prophylaxis strategy (Figure 
4). Prophylaxis caused a selection pressure for resistant 
strains;  the  percentage  of  infections  caused  by  resistant 
strains in the nursing home was higher than in the commu-
nity (Figure 5). The selection of resistant strains was most 
pronounced for continuous prophylaxis strategy.
Alternative Scenario: Prophylaxis Extended to HCWs
Extension  of  prophylaxis  strategies  to  include  both 
HCWs and patients offered little additional protection to 
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Figure 2. Effects of prophylaxis with oseltamivir on influenza virus infection and disease rates among nursing home patients. The effects 
of both postexposure and continuous prophylaxis strategies are shown for different proportions of resistant virus strains in the community 
and compared with a control setting without prophylaxis and resistance. Panels A and C, postexposure prophylaxis given to all patients; 
panel B and D, continuous prophylaxis for 8 weeks. BL, baseline.
Figure 3. Distribution of influenza virus infection attack rates among patients who received no prophylaxis, postexposure prophylaxis, and 
continuous prophylaxis, in the absence of resistance.RESEARCH
patients (Figure 6). In the absence of resistance, postexpo-
sure and continuous prophylaxis reduced the infection at-
tack rate in HCWs from 0.14 to 0.10 and 0.05, respectively. 
The attack rate among patients decreased from 0.19 to 0.12 
(RR 0.65) and 0.03 (RR 0.15), respectively. Taken togeth-
er, the DNP for infection (of either patient or HCW) was 
140 for postexposure prophylaxis and 366 for continuous 
prophylaxis; the total number of doses administered was 2 
× as high as in the scenario in which only patients received 
prophylaxis.
When the HCW vaccination rate was 0.1, the infection 
attack rate among patients without prophylaxis was 0.23. 
This could be reduced to 0.15 (RR 0.67) when postexpo-
sure prophylaxis was given to patients alone and to 0.14 
(RR 0.63) when it was given to HCWs as well (Figure 6). 
Continuous prophylaxis given to patients only or to both 
patients and HCWs could reduce the infection attack rate 
to 0.06 (RR 0.26) and 0.04 (RR 0.16), respectively. How-
ever, the number of doses required per department was 
approximately 6 × higher for continuous prophylaxis than 
for postexposure prophylaxis. Results of other alternative 
scenarios and the uncertainty analyses are described in the 
supporting information (online Technical Appendix).
Discussion
Our model predicts that in the absence of resistance, 
both postexposure prophylaxis and continuous prophylax-
is can reduce the number of influenza virus infections in 
nursing home patients during annual influenza epidemics. 
Although continuous prophylaxis will prevent more cases, 
postexposure prophylaxis prevents more cases per dose. If 
resistance to oseltamivir increases, both prophylaxis strate-
gies become less efficacious and less efficient, with more 
selection for resistance during continuous prophylaxis. Ex-
tension of prophylaxis to HCWs is not expected to have a 
large effect on the attack rates among patients.
For the results of our modeling study to be correctly 
interpreted,  we  must  discuss  some  possible  limitations. 
First, we did not distinguish between different subtypes 
of influenza circulating in the community. The oseltami-
vir-resistant strains that dramatically increased in number 
globally during the last 2 influenza seasons were all influ-
enza A (H1N1) strains and resistance against oseltamivir 
seemed to be limited to the N1 serotype only. During the 
2007–08 season, H1N1 strains were responsible for ap-
proximately 60% of influenza virus infections in Europe, 
which  is  uncommon  when  data  for  the  last  decade  are 
examined (34). The remaining influenza virus infections 
were caused by A/H3N2 subtype and B type viruses. Thus, 
even if all influenza A (H1N1) strains acquired resistance 
against oseltamivir, levels of resistance of >60% are not 
very probable unless resistance develops as well in the 
other influenza A subtypes and in influenza B. Second, we 
did not take into account de novo resistance in persons on 
prophylaxis. We assumed the probability of emergence of 
resistance was very low (26) and, as we studied a small 
population, the effect on the outcome was assumed to be 
negligible.  Third,  we  used  estimates  on  the  efficacy  of 
oseltamivir prophylaxis from household studies because 
we did not have data specific for elderly people. More ac-
curate assessment of efficacy and comparison of preven-
tive measures in nursing homes will require new estimates 
from studies in senior populations. Finally, we studied a 
30-bed department instead of an entire nursing home. If 
an outbreak occurs in 1 department, it might be necessary 
to start prophylaxis in other nearby departments as well. 
However, the effects of prophylaxis for individual depart-
ments will not be different.
Our model confirmed the beneficial effects of prophy-
laxis with oseltamivir in reducing the number of infections 
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Figure  4.  The  number  of  daily  doses  of  oseltamivir  needed  to 
prevent 1 influenza virus infection or disease (DNP). Results are 
shown  for  both  postexposure  (PE)  prophylaxis  and  continuous 
(cont) prophylaxis for increasing proportions of oseltamivir-resistant 
virus strains in the community.
Figure  5.  The  proportion  of  infections  with  oseltamivir-resistant 
influenza virus strains among nursing home patients for increasing 
proportions of resistance in the community.Prophylaxis Strategies to Prevent Influenza
and preventing large outbreaks as has been suggested by 
some  observational  and  experimental  studies  (7–9).  We 
have not considered the effects of prophylaxis on the num-
ber of complications or deaths, but these can be assumed 
to be somewhat higher than for infection because oseltami-
vir also prevents complications when taken after infection 
(9,35). Our results suggest a large difference in both effica-
cy and efficiency between the postexposure and continuous 
prophylaxis  strategies.  Although  continuous  prophylaxis 
can protect more patients, it also requires large stocks of 
antiviral drugs and is therefore costly; postexposure pro-
phylaxis might be the preferred strategy. Furthermore, our 
model suggests that extending prophylaxis to HCWs does 
not prevent many additional infections among patients when 
compared with prophylaxis of patients only. Even when the 
number of infections prevented in HCWs was included, the 
number of daily doses needed to prevent 1 infection was 
higher than the number of daily doses needed when prophy-
laxis was given to patients only. This prediction might be 
of use for the evaluation of influenza prevention guidelines 
for nursing homes. Currently, the Dutch guideline for pre-
vention of influenza in nursing homes recommends postex-
posure prophylaxis for both patients and HCWs (1). CDC 
recommends prophylaxis to nonvaccinated HCWs only, or 
in case of a mismatch between the vaccine strains and the 
circulating virus strains, to all HCWs (2). Although the lat-
ter strategy is expected to be more efficient, the effect on 
infection attack rates among patients will be less extensive 
than with prophylaxis of all HCWs. In the postexposure 
strategy, 1,388 doses of oseltamivir were given to HCWs 
for every additional prevented infection in a patient. This 
number was very high compared with the 7 HCW vaccina-
tions needed to prevent 1 infection in patients observed in 
our previous study (18). Therefore, protection of patients 
by reducing the number of infections in HCWs seems to be 
more efficiently obtained by increasing vaccine administra-
tion among HCWs than by including them in prophylaxis 
strategies.
Our study suggests that the selection pressure for re-
sistance is lower for postexposure than for continuous pro-
phylaxis. Moreover, the efficiency of postexposure prophy-
laxis appears to be less sensitive to the level of resistance 
than that of continuous prophylaxis. During the 2007–08 
influenza  season,  the  prevalence  of  oseltamivir-resistant 
influenza A (H1N1) strains in Europe increased from <1% 
in previous years (11) to 25% on average, with a national 
prevalence ranging from 2.5% in Spain up to 66% in Nor-
way (36). During the 2008–09 influenza season almost all 
influenza A (H1N1) strains were oseltamivir resistant (12). 
Oseltamivir use in Europe was low in both years and, in 
the absence of an apparent selection pressure for resistance, 
predicting whether resistance will disappear, persist, or in-
crease next season is difficult. Our findings indicate that 
increasing resistance should be included in the decision-
making process for prevention of influenza in healthcare 
settings. Use of other antiviral agents that are not as associ-
ated with resistance should be considered as an alternative 
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Figure 6. A) Average number of influenza virus infections among 
patients and B) average number of administered doses of oseltamivir 
in a 30-bed nursing home department during 1 influenza season. 
For the postexposure and continuous prophylaxis strategies, results 
are shown for prophylaxis of patients only (p) and of both patients 
and healthcare workers (HCWs) (p+h) and compared with a control 
setting without prophylaxis (–). HCW vaccination rates of 0.4 and 
0.1 are considered.RESEARCH
prevention strategy (37). Household studies  suggest that 
prophylaxis with zanamivir, for example, can give simi-
lar results as prophylaxis with oseltamivir (4). However, 
zanamir prophylaxis should be studied in more detail in the 
nursing home population. Future modeling studies should 
also address other relevant issues such as the use of com-
bination or cycling therapy approaches (38) to retain the 
protection offered by current antiviral drugs. 
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